Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLoans and Notes ReceivablesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Marimed (MRMD) Loans and Notes Receivables (2016 - 2025)

Marimed has reported Loans and Notes Receivables over the past 11 years, most recently at $866000.0 for Q4 2025.

  • Quarterly Loans and Notes Receivables rose 1565.38% to $866000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $866000.0 through Dec 2025, up 1565.38% year-over-year, with the annual reading at $866000.0 for FY2025, 1565.38% up from the prior year.
  • Loans and Notes Receivables was $866000.0 for Q4 2025 at Marimed, roughly flat from $866000.0 in the prior quarter.
  • Over five years, Loans and Notes Receivables peaked at $2.6 million in Q2 2023 and troughed at $39000.0 in Q2 2025.
  • The 5-year median for Loans and Notes Receivables is $128000.0 (2021), against an average of $572576.6.
  • Year-over-year, Loans and Notes Receivables surged 1976.38% in 2022 and then plummeted 98.03% in 2024.
  • A 5-year view of Loans and Notes Receivables shows it stood at $127000.0 in 2021, then surged by 1976.38% to $2.6 million in 2022, then crashed by 98.03% to $52000.0 in 2023, then changed by 0.0% to $52000.0 in 2024, then skyrocketed by 1565.38% to $866000.0 in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Loans and Notes Receivables are $866000.0 (Q4 2025), $866000.0 (Q3 2025), and $39000.0 (Q2 2025).